As a first result, we confirmed the strong association of IDH mutations with the tumor genomic profile [10]: virtually all 1p19q codeleted tumors are IDH mutated [17, 18] whereas IDH mutation is extremely rare in gliomas with EGFR amplification. This evidence concerns the gene IDH1 and central nervous system cancer.